KALA - Kala Pharmaceuticals: Solid Progress
"Cauliflower is nothing but cabbage with a college education." - Mark Twain
Today, we revisit Kala Pharmaceuticals (KALA). This intriguing small-cap concern posted solid Q4 results last week. We highlight key aspects for its fourth-quarter earnings report, take a look at what is on horizon for Kala, and update our investment thesis on this interesting ocular concern in the paragraphs below.
Company Overview
Kala Pharmaceuticals is a Massachusetts-based, commercial-stage "Tier 3" biopharmaceutical delivery company initially focused on the development of therapeutics for the treatment of eye diseases. The company employs a proprietary